Oxfordshire, UK, 17 July 2019 – Karus Therapeutics Ltd (‘Karus’), a clinical-stage biopharmaceutical company developing precision medicines for cancer, today announced the appointment of Dr Hilary McElwaine-Johnn, MD as Chief Medical Officer (CMO) with immediate effect. Dr McElwaine-Johnn is a Physician with over 25 years’ experience in drug development, most recently as CMO at cancer gene […]

Oxfordshire, UK, 18th September 2017 – Karus Therapeutics Ltd (‘Karus’), a leader in the design and development of innovative medicines with breakthrough potential in the treatment of cancer, today announced that the first patients have been dosed with its histone deacetylase 6 (HDAC6) inhibitor, KA2507, in a Phase I clinical study. This is the Company’s second […]

Oxford, UK, 1 May 2017 – Karus Therapeutics Ltd, a leader in the development of innovative medicines for the treatment of cancer, has announced its Chief Scientific Officer will be delivering a presentation at the 18th Annual Drug Discovery Summit/5th Annual Discovery Chemistry & Drug Design Congress, Berlin, 13 June 2017. Stephen Shuttleworth, COO & […]

First cohort of cancer patients has been dosed with Karus’s lead candidate, KA2237 Potential first-in-class dual-PI3K-p110β/δ inhibitor with broad potential to treat hematological and solid tumors KA2237 combines an immunotherapeutic response and a direct effect on tumor growth Oxford, UK, 5 October 2016 – Karus Therapeutics (‘Karus’), a leader in the development of innovative, orally-active […]

Oxford, UK, 7 September 2016 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of cancer, has announced its CSO will be attending and delivering a lecture at the 9th Annual Kinase Inhibitor Discovery conference, Boston, USA, 19 September 2016. Stephen Shuttleworth, Karus’s CSO, will be lecturing in the session Role […]